drugset / Trial / NCT05469802
A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to describe the side effects and immune response of a candidate vaccine that might protect against Zika. The vaccine called PIZV (purified inactivated Zika virus vaccine) is given by injection in two doses that are 28 days apart in healthy adults. Participants will receive PIZV or placebo and will be followed for 7 days after each dose and up to 6 months after dose 2.
Timeline
- Start
- 2024-01-02
- Primary completion
- 2024-07-05
- Completion
- 2024-07-05
Outcome
Outcome not reported
Stopped (Business): “Business reason, change in Zika virus epidemiology”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Purified Inactivated Zika Virus Vaccine | Unknown | 0.5 ml | Intramuscular |
Indications
No indication recorded.